Options Action: Traders making big bets on Uber
Mike Khouw, Optimize Advisors president, joins the Options Action traders to talk big bets on Uber.
Similar Posts
Ret. U.S. Army Col. Jacobs on Red Sea tensions: The U.S. should attack the Houthi rebels in Yemen
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Retired U.S. Army Col. Jack Jacobs joins ‘Squawk Box’ to discuss the latest developments in the Red Sea following recent large-scale attacks by Iran-backed Houthi rebels, what the U.S. response should be, the impact on U.S.-Iran tensions, and more. 05:10 Thu, Jan…
How beer benefits the US economy
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Beer is the most popular alcoholic drink in the U.S. But did you know the beer industry employs over 2 million Americans? 00:53 Tue, Apr 7 20154:00 PM EDT
Boeing CEO Dave Calhoun calls the Alaska Airlines incident a ‘mistake’ that should never happen
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Boeing CEO Dave Calhoun joins ‘The Exchange’ to discuss the Alaska Airlines incident, how the company is addressing this, and more. 04:00 Wed, Jan 10 20241:22 PM EST
Options Action: Tesla jumps ahead of Q3 production and delivery numbers
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Fast Money Mike Khouw, Optimize Advisors president, joins CNBC’s Melissa Lee and the Options Action traders talk Tesla. 01:18 Fri, Sep 29 20236:08 PM EDT
Hon Hai can manage chip shortages, focus on its EV plans instead: Strategist
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Kirk Yang from Kirkland Capital says Hon Hai’s shares are “little expensive” as investors have already priced in their expectations for the chipmaker’s EV plans. 02:37 Wed, Mar 31 20214:49 AM EDT
Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.
